SOURCE: World Street Fundamentals

June 28, 2011 09:00 ET

Equity Research on Icagen, Inc. and Celgene Corporation - Biopharmaceuticals Have the Cure

HONG KONG--(Marketwire - Jun 28, 2011) - Today, released its industry report highlighting Icagen, Inc. (NASDAQ: ICGN) and Celgene Corporation (NASDAQ: CELG). Full fundamental and technical analysis is available at

This sector demonstrates renewed investor interest as new and lucrative therapies come to market. The FDA approved the first new drug in 50 years to treat auto-immune disorder lupus in March 2011, and we expect approval of new treatments for Hepatitis C virus around mid-year. The 2010 health care reform act authorized by the FDA, will establish a regulatory pathway for approving "biosimilar" drugs, which in turn will increase production and shorten FDA approval times. Longer term, it is expected that a wider acceptance of biomarker research and genetic-targeted clinical studies to help limit expense. It is viewed that therapeutics for cancer and infectious diseases and autoimmune and inflammatory treatments are primary growth areas.

World Street Fundamentals has highlighted Icagen, Inc. as a biopharmaceutical company focused on the discovery, development and commercialization of orally-administered small molecule drugs that modulate ion channel targets. The Company's principal program is ICA-105665 for epilepsy and pain, for which the Company has completed a proof-of-concept trial in epilepsy with positive results and a proof-of-concept trial in pain with negative results. The Company is also conducting ongoing drug discovery programs focused on new therapeutics for pain and inflammatory disorders. (NASDAQ: ICGN) is available here:

World Street has highlighted Celgene Corporation as an integrated biopharmaceutical company primarily engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases. It is involved in research in several scientific areas that may deliver therapies, targeting areas such as intracellular signaling pathways in cancer and immune cells, immunomodulation in cancer and autoimmunity and placental cell, including stem and progenitor cell, research. The drug and cell therapies it develops are designed to treat life-threatening diseases or chronic debilitating conditions. The entire report on Celgene Corporation (NASDAQ: CELG) is available here:

About World Street
World Street Fundamentals is an online portal for professionals, investors and new-comers to the markets to find in depth comprehensive research and research tools to help guide you through the ever changing financial markets. Covering the top performers in the hottest sectors and providing clarity to investors around the world.

Contact Information